Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
Overview
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
Associated Conditions
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Acute Promyelocytic Leukemia
- Meningeal leukemia
- Metastatic Malignant Neoplasm to the Leptomeninges
- Non-Hodgkin's Lymphoma (NHL)
- Treatment-Related Acute Myeloid Leukemia
- Blast phase Chronic myeloid leukemia
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2008/01/28 | Phase 1 | Completed | |||
2008/01/15 | Phase 2 | Terminated | |||
2008/01/11 | Phase 2 | Completed | |||
2007/12/31 | Phase 1 | Terminated | |||
2007/12/20 | Phase 2 | Completed | |||
2007/12/20 | Phase 3 | Completed | |||
2007/12/14 | Phase 3 | Terminated | |||
2007/12/12 | Early Phase 1 | Completed | |||
2007/12/06 | Phase 1 | Completed | |||
2007/11/15 | Phase 2 | UNKNOWN |
FDA Approved Products
View More FDA Products
Sign in to access additional FDA-approved products with detailed regulatory information.
Product Name | Manufacturer | Route | Strength | Approved | NDC Code |
|---|
No FDA products found
No FDA products found for this drug
EMA Approved Products
View More EMA Products
Sign in to access additional EMA-approved products with authorization details.
Medicine Name | EMA Number | Auth. Holder | Country | Drug Type | Status | Issued | Opinion | Revision |
|---|
No EMA products found
No EMA products found for this drug
HSA Approved Products
View More HSA Products
Sign in to access additional HSA-approved products with regulatory information.
Product Name | Manufacturer | Dosage Form | Strength | Approved | Approval No. |
|---|
No HSA products found
No HSA products found for this drug
NMPA Approved Products
View More NMPA Products
Sign in to access additional NMPA-approved products with approval information.
Product Name | Approval No. | Manufacturer | Dosage Form | Trade Name | Strength | Type | Status | Date | Import |
|---|
No NMPA products found
No NMPA products found for this drug
PPB Approved Products
Product Name | Registration Code | Company | Category | Sale Type | Reg. Date |
|---|---|---|---|---|---|
HK-66210 | Part 1, Schedule 1 & Schedule 3 Poison | POM | 2019/04/29 |
TGA Approved Products
View More TGA Products
Sign in to access additional TGA-approved products with licensing information.
Product Name | ARTG ID | Sponsor | Status | Reg. Date | Ingredient |
|---|
No TGA products found
No TGA products found for this drug